Topical dermatological drug delivery: Quo vadis?

Current Drug Delivery

Volumn 7, Issue 4, 2010, Pages 283-296

  Akomeah, Franklin K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biologics; Dermatological; Drug delivery; Formulation; Patient compliance; Skin absorption; Topical bioavailability

Indexed keywords

ACICLOVIR; ADRENALIN; BIOPOLYMER; CAFFEINE; CISPLATIN; COPPER SULFATE; CYCLOSPORIN; DECYL METHYL SULFOXIDE; DURHALIEVE; FENTANYL; HISTAMINE; HYALURONIC ACID; IDOXURIDINE; LIDOCAINE; LIPOSOME; METHOTREXATE; METHYLPREDNISOLONE; MICROSPHERE; NANOPARTICLE; POLYMER; POTASSIUM IODIDE; PRILOCAINE; SALICYLATE SODIUM; TERBINAFINE; TRANILAST; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VINBLASTINE; ZINC OXIDE;

AEROSOL; ARTICLE; CREAM; DERMATOPHYTOSIS; DEVICE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FOAM; GEL; HERPES SIMPLEX; HYPERTROPHIC SCAR; IONTOPHORESIS; KELOID; LICHEN PLANUS; LOTION; OINTMENT; ONYCHOMYCOSIS; PASTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; SKIN ABSORPTION; SKIN CARCINOMA; SKIN DEFECT; SKIN TEMPERATURE; SPOROTRICHOSIS; TOPICAL TREATMENT; ULCER; ULTRASOUND; VERRUCA VULGARIS; WOUND DRESSING;

ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, STRUCTURAL;

EID: 77958507789     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110793360612     Document Type: Article

References (149)

1. Thorpe, K.E.; Florence, C.S.; Joski, P. Which medical conditions account for the rise in health spending? Health Aff. (Suppl Web Exclusives), 2004, W4-437-445.
2. Bickers, D.R.; Lim, H.W.; Margolis, D.; Weinstock, M.A.; Goodman, C.; Faulkner, E.; Gould, C.; Gemmen, E.; Dall, T. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J. Am. Acad. Dermatol., 2006, 55, 490-500.
3. IMS health data from Nova Secta presentation on dermatology opportunities for mid-sized Companies. Available: http://hugin.info/131151/R/1350766/326138.pdf [Last accessed 24 November 2010].
4. R&D Directions Staff. Biologics the focus of skin disease. R & D Directions., 2009, 15, 26.
5. Brown, M.B.; Martin, G.P.; Jones, S.A.; Akomeah, F.K. Dermal and transdermal drug delivery systems: current and future prospects. Drug. Deliv., 2006, 13, 175-187.
6. Walters K.A. Dermatological and Transdermal Formulations, Marcel Dekker: New York, 2002.
7. Surber, C.; Itin, P.; Büchner, S. Clinical controversy on the effect of topical ciclosporin: what is the target site? Dermatology, 1992, 185, 242-245.
8. Pariser, D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of a topic dermatitis: focus on percutaneous absorption. Am. J. Ther., 2009, 16, 264-273.
9. Castro, G.A.; Ferreira, L.A. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert. Opin. Drug. Deliv., 2008, 5, 665-679.
10. Hadgraft, J. Skin, the final frontier. Int. J. Pharm., 2001, 224, 1-18.
11. Walter, K.; Kurz H. Binding of drugs to human skin: influencing factors and the role of tissue lipids. J. Pharm. Pharmacol., 1988, 40, 689-693.
12. Hagedorn-Leweke, U.; Lippold, B.C. Accumulation of sunscreens and other compounds in keratinous substrates. Eur. J. Pharm. Biopharm., 1998, 46, 215-221
13. Yagi, S.; Nakayama, K.; Kurosaki, Y.; Higaki, K.; Kimura T. Factors determining drug residence in skin during transdermal absorption: studies on beta-blocking agents. Biol. Pharm. Bull., 1998, 21, 1195-1201.
14. Banning, T.P.; Heard, C.M. Binding of doxycycline to keratin, melanin and human epidermal tissue. Int. J. Pharm., 2002, 235, 219-227.
15. Roberts, M.S., Cross, S.E., Anissimov, Y.G. Factors affecting the formation of a skin reservoir for topically applied solutes. Skin. Pharmacol. Physiol., 2004, 17, 3-16.
16. El-Mahrab, R. M.; Kalia, Y. N. New developments in topical antifungal therapy. Am. J. Drug. Deliv., 2006, 4, 231-247.
17. Billich, A.; Vyplel, H.; Grassberger, M.; Schmook, F.P.; Steck, A.; Stuetz, A. Novel cyclosporin derivatives featuring enhanced skin penetration despite increased molecular weight. Bioorg. Med. Chem., 2005, 13, 3157-3167.
18. Marieb, E. N. Human Anatomy and Physiology, (4th ed.). Benjamin Cummings, San Francisco, 1997.
19. Stoughton, R.B. Are generic formulations equivalent to trade name topical glucocorticoids. Arch. Dermatol., 1987, 123, 1312-1314.
20. Shah, V.P.; Flynn, G.L.; Yacobi, A.; Maibach, H. I.; Bon, C.; Fleischer, N.M.; Franz, T.J.; Kaplan, S.A.; Kawamoto, J.; Lesko, L.J.; Marty, J.P.; Pershing, L.K.; Schaefer, H.; Sequeira, J.A.; Shrivastava, S.P.; Wilkin, J.; Williams, R.L. Bioequivalence of topical dermatological dosage forms-methods of evaluation of bioequivalence. AAPS/FDA Workshop on 'Bioequivalence of Topical Dermatological Dosage Forms- Methods of Evaluating Bioequivalence, September 4-6, 1996, Bethesda, MD. Skin. Pharmacol. Appl. Skin. Physiol., 1998, 11, 117-124.
21. Wiedersberg, S.; Leopold, C.S.; Guy, R.H. Bioavailability and bioequivalence of topical glucocorticoids. Eur. J. Pharm. Biopharm., 2008, 68, 453-466.
22. Ingber, A. Breaking the rules of topical skin therapeutics. Skinmed, 2003, 2, 181.
23. Lodén, M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am. J. Clin. Dermatol., 2003, 4, 771-788.
24. Lodén, M.; Buraczewska, I.; Edlund, F. Irritation potential of bath and shower oils before and after use: a double-blind randomized study. Br. J. Dermatol., 2004, 150, 1142-1147.
25. Rapp, S.R.; Exum, M.L.; Reboussin, D.M.; Feldman, S.R.; Fleischer, A.; Clark, A. The physical, psychological and social impact of psoriasis. J. Health. Psychol., 1997, 2, 525-537.
26. Housman, T.S.; Mellen, B.G.; Rapp, S.R.; Fleischer, A.B. Jr.; Feldman, S.R. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis, 2002, 70, 327-332.
27. Feldman, S.R.; Horn, E.J.; Balkrishnan, R.; Basra, M.K.; Finlay, A.Y.; McCoy, D.; Menter, A.; van de Kerkhof, P.C. International Psoriasis Council. Psoriasis: improving adherence to topical therapy. J. Am. Acad. Dermatol., 2008, 59, 1009-1016.
28. Zivkovich, A.H.; Feldman, S.R. Are ointments better than other vehicles for corticosteroid treatment of psoriasis. J. Drugs Dermatol., 2009, 8, 570-572.
29. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Deliv. Rev., 2004, 56, 603-618.
30. López, A.; Pellett, M.A.; Llinare, F.; Díez-Sales, O.; Herráez M.; Hadgraft, J. The enhancer effect of several phenyl alcohols on percutaneous penetration of 5-Fluorouracil. Pharm. Res., 1997, 14, 681-685.
31. Shokri, J.; Nokhodchi, A.; Dashbolaghi, A.; Hassan-Zadeh, D.; Ghafourian, T.; Barzegar Jalali, M. The effect of surfactants on the skin penetration of diazepam. Int. J. Pharm., 2001, 228, 99-107.
32. Tupker, R.A.; Pinnagoda, J.; Nater, J.P. The transient and cumulative effect of sodium lauryl sulphate on the epidermal barrier assessed by transepidermal water loss: inter-individual variation. Acta. Dermatol. Venereol. (Stockh)., 1990, 70, 1-5.
33. Karande, P.; Jain, A.; Mitragotri, S. Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery. J. Control Release, 2006, 115, 85-93.
34. Valenta, C.; Auner, B.G. The use of polymers for dermal and transdermal delivery. Eur. J. Pharm. Biopharm., 2004, 58, 279-289.
35. Brown, M.B.; Jones, S.A. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J. Eur. Acad. Dermatol. Venereol., 2005, 19, 308-318.
36. Brown, M.B.; Hanpanitcharoen, M.; Martin, G.P. An in vitro investigation into the effect of glycosaminoglycans on the skin partitioning and deposition of NSAIDs. Int. J. Pharm., 2001, 225, 113-121.
37. Lin, W.; Maibach, H.I. In Hyaluronan in Drug Delivery; Willoughby D, Ed.; Royal Society of Medicine Press: London, 1996, pp. 167-174.
38. Jarvis, B.; Figgitt, D.P. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Am. J. Clin. Dermatol., 2003, 4, 203-213.
39. Nelson, C.; Rigel, D.; Smith, S.; Swanson, N.; Wolf, J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J. Drugs Dermatol., 2004, 3, 401-407.
40. Brown, M.B.; Marriott, C.; Martin, G.P. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int. J. Tissue React., 1995, 17, 133-140.
41. Brown, M.B.; Jones, S.A.; Weijiang, H.E.; Martin, G.P. Hyaluronan. In Polysaccharides for drug delivery and pharmaceutical applications (ACS symposium series), Marchessault, R.H, Ed.; American Chemical Society: Washington DC, 2006; Vol. 934, pp. 141-153.
42. Bangham, A.D. In Liposomes in biological systems, Gregoriadis, G.; Allison, A.C. Eds., John Wiley and Sons: UK, 1980, pp. 1-24.
43. Gulati, M.; Grover, M.; Singh, S.; Singh, M. Lipophilic drug derivatives in liposomes. Int. J. Pharm., 1998, 165, 129-168.
44. Kirjavainen, M.; Mönkkönen, J.; Saukkosaari, M.; Valjakka-Koskela, R.; Kiesvaara, J.; Urtti, A.; Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers. J. Control Release, 1999, 58, 207-214.
45. Mezei, M.; Gulasekharam, V. Liposomes--a selective drug delivery system for the topical route of administration: lotion dosage form. Life Sci., 1980, 26, 1473-1477.
46. Mezei, M.; Gulasekharam, V. Liposomes--a selective drug delivery system for the topical route of administration: gel dosage form. J. Pharm. Pharmacol., 1982, 34, 473-474
47. Skalko, N.; Cajkovac, M.; Jalsenjak, I. Liposomes with clindamycin hydrochloride in the therapy of acne vulgaris. Int. J. Pharm., 1992, 85, 97-101.
48. Korting, H.C.; Zienicke, H.; Schäfer-Korting, M.; Braun-Falco, O. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur. J. Clin. Pharmacol., 1990, 39, 349-351.
49. Bucalo, B.D.; Mirikitani, E.J.; Moy, R.L. Comparison of skin anaesthetic effect of liposomal lidocaine, non-liposomal lidocaine, and EMLA using 30-minute application time. Dermatol. Surg., 1998, 24, 537-541.
50. Korting, H.; Kloverkorn, G. Comparative efficacy and tolerability of econazole liposomal gel 1%, branded econazole conventional cream 1% and generic clotrimazole 1% in tinea pedis. Clin. Drug Invest., 1997, 14, 286-293.
51. du Plessis, J.; Egbaria, K.; Ramachandran, C.; Weiner, N. Topical delivery of liposomally encapsulated gamma-interferon. Antiviral. Res., 1992, 18, 259-265.
52. Li, L.; Hoffman, R.M. Topical liposome delivery of molecules to hair follicles in mice. J. Dermatol. Sci., 1997, 14, 101-108
53. Targeted follicular delivery of macromolecular via liposomes. Int. J. Pharm., 1998, 162, 29-38.
54. Vogt, A.; Mandt, N.; Lademann, J.; Schaefer, H.; Blume-Peytavi, U. Follicular targeting--a promising tool in selective dermatotherapy. J. Investig. Dermatol. Symp. Proc., 2005, 10, 252-255.
55. Lasch, J.; Laub, R.; Wohlrab, W. How deep do intact liposomes penetrate into human skin? J. Control Release, 1991, 18, 55-58.
56. Hope, M.J.; Kitson, C.N. Liposomes. A perspective for dermatologists. Dermatol. Clin. 1993, 11, 143-154.
57. Schreier, H.; Bouwstra, J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J. Control Release, 1994, 30, 1-15.
58. El Maghraby, G.M.; Williams A.C.; Barry, B.W. Can drug-bearing liposomes penetrate intact skin? J. Pharm. Pharmacol. 2006, 58, 415-429.
59. Sinico, C.; Fadda, A.M. Vesicular carriers for dermal drug delivery. Expert. Opin. Drug Deliv. 2009, 6, 813-825.
60. Fesq, H.; Lehmann, J.; Kontny, A.; Erdmann, I.; Theiling, K.; Rother, M.; Ring, J.; Cevc, G.; Abeck, D. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. Br. J. Dermatol., 2003, 149, 611-619.
61. Seth, A.K.; Misra, A.; Umrigar, D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. Pharm. Dev. Technol., 2004, 9, 277-289.
62. Gong, J.H.; Liu, Y.; Tang, L.H.; Xu, X.J.; Zhang, X.N. An alternative lidocaine hydrochloride liposomal gel formulation: preparation, percutaneous permeation, and release kinetics. PDA. J. Pharm. Sci. Technol., 2006, 60, 259-263.
63. Elron-Gross, I.; Glucksam, Y.; Margalit, R. Liposomal dexamethasone-diclofenac combinations for local osteoarthritis treatment. Int. J. Pharm., 2009, 376, 84-91.
64. Manconia, M.; Pendás, J.; Ledón, N.; Moreira, T.; Sinico, C.; Saso, L.; Fadda, A.M. Phycocyanin liposomes for topical anti-inflammatory activity: in-vitro in-vivo studies. J. Pharm. Pharmacol., 2009, 61, 423-430.
65. Helix Biopharma Phase 2 trial of topical interferon alpha-2b in patients with genital warts. http://www.helixbiopharma.com/Portals/0/investors/News%20Releases/English/Current/Press_Mar22_2010_EN.pdf [accessed April 27, 2010].
66. Benita, S. Microencapsulation: methods and industrial applications (drugs and the pharmaceutical sciences), CRC Press: Boca Raton, 2005.
67. Chadawar, V.; Shaji, J. Microsponge Delivery system. Curr. Drug. Deliv., 2007, 4, 123-129.
68. Lademann, J.; Schaefer, H.; Otberg, N.; Teichmann, A.; Blume-Peytavi, U.; Sterry, W. Penetration of microparticles in skin. Hautarzt, 2004, 55, 1117-1119.
69. Toll, R.; Jacobi, U.; Richter, U.; Lademann, T.; Schaefer, H.; Blume-Peytavi, U. Penetration Profile of Microspheres in Follicular Targeting of Terminal Hair Follicles. J. Invest. Dermatol., 2004, 123, 168-176.
70. Date, A.A.; Naik, B.; Nagarsenker, M.S. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin. Pharmacol. Physiol., 2006, 19, 2-16.
71. Leyden, J.J.; Grossman, R.; Nighland, M. Cumulative irritation potential of topical retinoid formulations. J. Drugs. Dermatol., 2008, 7(8 Suppl), 14-18.
72. Smith, S.; Morhenn, V.; Webster, G. The characteristics and utility of solid phase porous microspheres: a review. J. Drugs. Dermatol., 2006, 5, 969-974.
73. Webster, G.F. Topical tretinoin in acne therapy. J. Am. Acad. Dermatol., 1998, 39(Suppl), S38-44.
74. Nighland, M.; Yusuf, M.; Wisniewski, S.; Huddleston, K.; Nyirady, J. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis, 2006, 77, 313-316.
75. Nyirady, J.; Lucas, C.; Yusuf, M.; Mignone, P.; Wisniewski, S. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis, 2002, 70, 295-298.
76. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug. Del. Rev. 2001, 47, 165-196
77. Pardeike, J.; Hommoss, A.; Müller, R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal product. Int. J. Pharm., 2009, 366, 170-184.
78. Schäfer-Korting, M.; Mehnert, W.; Korting, H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug. Deliv. Rev., 2007, 59, 427-443.
79. Müller, R.H.; Petersen, R.D.; Hommoss, A.; Pardeike, J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug. Deliv. Rev., 2007, 59, 522-530.
80. Fang, J.Y.; Fang, C.L.; Liu, C.H.; Su, Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm., 2008, 70, 633-640.
81. Kalariya, M.; Padhi, B.K.; Chougule, M.; Misra, A. Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications. Indian. J. Exp. Biol., 2005, 43, 233-240.
82. Huang, X.; Tanojo, H.; Lenn, J.; Deng, C.H.; Krochmal, L. A novel foam vehicle for delivery of topical corticosteroids. J. Am. Acad. Dermatol., 2005, 53(Suppl 1), S26-38.
83. Reid, M.L.; Brown, M.B.; Jones, S.A. Manipulation of corticosteroid release from a transiently supersaturated topical metered dose aerosol using a residual miscible co-solvent. Pharm. Res., 2008, 25, 2573-2580.
84. Jones, S.A.; Reid, M.L.; Brown, M.B.; Determining degree of saturation after application of transiently supersaturated metered dose aerosols for topical delivery of corticosteroids. J. Pharm. Sci., 2009, 98, 543-554.
85. Zhao, Y.; Brown, M.B.; Jones, S.A. Pharmaceutical foams: are they the answer to the dilemma of topical nanoparticles? Nanomedicine. 2009, (in press)
86. Tamarkin D, Friedman D, Shemer A. Emollient foam in topical drug delivery. Expert Opin. Drug. Deliv. 2006, 3, 799-807.
87. Purdon, C.H.; Haigh, J.M.; Surber, C; Smith, E.W. Foam drug delivery in dermatology: beyond the scalp. Am. J. Drug Deliv., 2003, 1, 71-75.
88. Reid, M.L.; Jones, S.A.; Brown, M.B. Transient drug supersaturation kinetics of beclomethasone dipropionate in rapidly drying films. Int. J. Pharm., 2009, 371, 114-119.
89. Stein, L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J. Am. Acad. Dermatol., 2005, 53(Suppl 1), S39-49.
90. Frangos, J.E., Kimball, A.B. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opin. Pharmacother., 2008, 9, 2001-2007.
91. Beutner, K.; Chakrabarty, A.; Lemke, S.; Yu, K. An intraindividual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J. Drugs. Dermatol., 2006, 5, 357-360.
92. Feldman, S.R.; Yentzer, B. A. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am. J. Clin. Dermatol., 2009, 10, 397-406.
93. Bucks, D.A.; McMaster, J.R.; Maibach, H.I.; Guy, R.H. Bioavailability of topically administered steroids: a mass balance technique. J. Invest. Dermatol., 1988, 91, 29-33.
94. Zhai, H.; Maibach, H.I. Effects of skin occlusion on percutaneous absorption: an overview. Skin. Pharmacol. Appl. Skin. Physiol., 2001, 14, 1-10.
95. Hartmann, A.; Bröcker, E.B.; Hamm, H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Acta. Dermatol. Venereol., 2008, 88, 474-479.
96. Kragballe, K.; Larsen, F.G. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta. Dermatol. Venereol., 1991, 71, 540-542.
97. Wilkinson, R.D.; Ohayon, M. Therapeutic response to a dermatologic patch and betamethasone valerate 0.1 percent cream in the management of chronic plaques in psoriasis. Cutis, 1990, 45, 468-470.
98. González, J. R.; Cabán, F. Treatment of psoriasis with triamcinolone acetonide 0.1% under occlusion: a comparison of two hydrocolloid dressings. Bol. Asoc. Med. P.R., 1990, 82, 288-291.
99. Hollingsbee, D.A.; Fairbrother, J.E.; Martin, G.P.; Marriott, C.; Monger, L. The effect of a hydrocolloid dermatological patch (Actiderm) in potentiating the skin blanching activity of triamcinolone acetonide. Int. J. Pharm., 1991, 77, 199-209.
100. van de Kerkhof, P.C.; Chang, A.; van der Walle, H.B.; van Vlijmen-Willems, I.; Boezeman, J.B.; Huigen-Tijdink, R. Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. Acta. Dermatol. Venereol., 1994, 74, 143-146.
101. Zhai, H.; Maibach, H.I. Skin occlusion and irritant and allergic contact dermatitis: an overview. Contact Dermatitis, 2001, 44, 201-206.
102. Hogan, D.J.; Maibach, H.I. Adverse dermatologic reactions to transdermal drug delivery systems. J. Am. Acad. Dermatol., 1990, 22, 811-814.
103. Chen, J.Z.; Alexiades-Armenakas, M.R.; Bernstein, L.J.; Jacobson, L.G.; Friedman P.M.; Geronemus, R.G. Two randomized, doubleblind, placebo-controlled studies evaluating the S-Caine Peel for induction of local anesthesia before long-pulsed Nd:YAG laser therapy for leg veins. Dermatol. Surg., 2003, 29, 1012-1018.
104. Doshi, S.N.; Friedman, P.M.; Marquez, D.K.; Goldberg, L.H. Thirty-minute application of the S-Caine peel prior to non-ablative laser treatment. Dermatol. Surg., 2003, 29, 1008-1011.
105. Alster T.S. The lidocaine/tetracaine peel: a novel topical anesthetic for dermatologic procedures in adult patients. Dermatol. Surg., 2007, 33, 1073-1081.
106. Bryan, H.A.; Alster, T.S. The S-Caine peel: a novel topical anesthetic for cutaneous laser surgery. Dermatol. Surg., 2002, 28, 999-1003.
107. Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis (Clinical Trials Database, US National institute of Health). Available: http://clinicaltrials.gov/ct2/show/NCT00890968?term=durapeel&rank=1. [Last accessed 23 November 2009].
108. Akomeah, F.; Nazir, T.; Martin, G.P.; Brown, M.B. Effect of heat on the percutaneous absorption and skin retention of three model penetrants. Eur. J. Pharm. Sci., 2004, 21, 337-345.
109. Ogiso, T.; Hirota, T.; Masahiro, I.; Hino, T.; Tadatoshi, T. Effect of temperature on percutaneous absorption of terodiline and relationship between penetration and fluidity of stratum corneum lipids. Int. J. Pharm., 1998, 176, 63-72.
110. Hull, W. Heat-enhanced transdermal drug delivery: a survey paper. J. Appl. Res. Clin. Exp. Ther., 2002, 2, 1-9. http://jarcet.com/articles/Vol2Iss1/Hull.htm (Accessed May 11, 2009).
111. Liu, D.R.; Kirchner, H.L.; Petrack, E.M. Does using heat with eutectic mixture of local anaesthetic cream shorten analgesic onset time? A randomized, placebo-controlled trial. Ann. Emerg. Med., 2003, 42, 27-33.
112. Tadicherla, S.; Berman, B. Percutaneous dermal drug delivery for local pain control. Ther. Clin. Risk. Manag., 2006, 2, 99-113.
113. Sawyer, J.; Febbraro, S.; Masud, S.; Ashburn, M.A.; Campbell, J.C. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Br. J. Anaesth., 2009, 102, 210-215.
114. Doherty, C.B.; Doherty, S.D.; Rosen, T. Thermotherapy in dermatologic infections. J. Am. Acad. Dermatol., 2010, 62, 909-927.
115. Behl, C.R.; Flynn, G.L.; Kurihara, T.; Smith, W.; Gatmaitan, O.; Higuchi, W.I.; Ho, N.F.; Pierson, C.L. Permeability of thermally damaged skin (I): immediate influences of 60 °C scalding on hairless mouse skin. J. Invest. Dermatol., 1980, 75, 340-345.
116. Guy, R.H.; Kalia, Y.N.; Delgado-Charro, M.B.; Merino, V.; Lopez, A.; Marro, D. Iontophoresis: electrorepulsion and electroosmosis, J. Control Release, 2000, 64, 129-132.
117. Kalia, Y.N.; Naik, A.; Garrison, J.; Guy, R.H. Iontophoretic drug delivery. Adv. Drug Deliv. Rev., 2004, 56, 619-658.
118. Akomeah, F.; Martin, G.P.; Brown, M.B. Short-term iontophoretic and post-iontophoretic transport of model penetrants across excised human epidermis. Int. J. Pharm., 2009, 367, 162-168.
119. Turner, N.G.; Kalia, Y.N.; Guy, R.H. The effect of current on skin barrier function in vivo: recovery kinetics post-iontophoresis. Pharm. Res., 1997, 14, 1252-1257.
120. Riviere, J.E.; Monteiro-Riviere, N.A.; Inman, A.O. Determination of lidocaine concentrations in skin after transdermal iontophoresis: effects of vasoactive drugs, Pharm. Res., 1992, 18, 1709-1713.
121. Morrel, E.M.; Spruance, S.L.; Goldberg, D.I.; Iontophoretic Acyclovir Cold Sore Study Group. Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. Clin. Infect. Dis., 2006, 43, 460-467.
122. Kassan, D.G.; Lynch, A.M.; Stiller, M.J. Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. J. Am. Acad. Dermatol., 1996, 34, 657-666.
123. Oshima, T.; Kashiki, K.; Toyooka, H.; Masuda, A.; Amaha, K. Cutaneous iontophoretic application of condensed lidocaine. Can. J. Anaesth., 1994, 41, 677-679.
124. Ozawa, A.; Haruki, Y.; Iwashita, K.; Sasao, Y.; Miyahara, M.; Sugai, J.; Matsuyama, T.; Iizuka, M.; Kawakubo, Y.; Nakamori, M.; Ohkido, M. Follow-up of clinical efficacy of iontophoresis therapy for postherpetic neuralgia (PHN). J. Dermatol., 1999, 26, 1-10.
125. Parry, G.E.; Dunn, P.; Shah, V.P.; Pershing, L.K. Acyclovir bioavailability in human skin. J. Invest. Dermatol., 1992, 98, 856-863.
126. Shaw, M.; Kling, M.; Best, J.M.; Banatvala, J.E.; Gibson, J.R.; Klaber, M.R. Failure of acyclovir cream in treatment of recurrent herpes labialis. Br. Med. J., 1985, 291, 7-9.
127. Akomeah, F.; Martin, G.P.; Muddle, A.G.; Brown, M.B. Effect of abrasion induced by a rotating brush on the skin permeation of solutes with varying physicochemical properties. Eur. J. Pharm. Biopharm., 2008, 68, 724-734.
128. Shukla, C.; Friden, P.; Juluru, R.; Stagni, G. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations. J. Pharm. Sci., 2009, 98, 917-925.
129. Murdan, S. Drug delivery to the nail following topical application. Int. J. Pharm., 2002, 236, 1-26.
130. Baran, R.; Hay, R.J.; Garduno, J.I. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J. Dermatol. Treat., 2008, 19, 72-81.
131. Baran, R.; Hay, R.J.; Garduno, J.I. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J. Dermatol. Treat., 2008, 19, 168-175.
132. Nair, A.B.; Kim, H.; Chakraborty, B.; Singh, J.; Zaman, M.; Gupta, A.; Friden, P.M; Murthy, S.N. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J. Pharm. Sci., 2009, 98, 4130-4140.
133. Nair, A.B.; Kim, H.D.; Davis, S.P.; Etheredge, R.; Barsness, M.; Friden, P.M.; Murthy, S.N. An ex vivo toe model used to assess applicators for the iontophoretic ungual delivery of terbinafine. Pharm Res., 2009, 26, 2194-2201.
134. Amichai, B.; Nitzan, B; Mosckovitz; Shemer, A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br. J. Dermatol., 2010, 62, 46-50.
135. Vali, A.; Asilian, A.; Khalesi, E.; Khoddami, L.; Shahtalebi, M.; Mohammady, M. Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris, J. Dermatol. Treat., 2005, 16, 234-237.
136. Yamamura, J.; Koyashu, M.; Sat, H.; Kurokawa, M.; Yoshida, Y.; Amahabu, Y.; Shiraki, K. Topical treatment of cutaneous herpes simplex virus-1 infection in mice with a specially formulated caffeine gel (Cafon). J. Dermatol. Sci., 1996, 12, 50-55.
137. Yoshida, Y.; Yamamura, J.; Sato, H.; Koyasu, M.; Obara, Y.; Sekiguchi, H.; Kawana, T.; Shiraki, K. Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV)-2 and acyclovirresistant HSV in mice. J. Dermatol. Sci., 1996, 13, 237-241.
138. Rawlings, A.V. Cellulite and its treatment. Int. J. Cosmet. Sci., 2006, 28, 175-190.
139. Velasco, M.V.; Tano, C.T.; Machado-Santelli, G.T.; Consiglieri, V.O.; Kaneko, T.M.; Baby, A.R.; Effects of caffeine and siloxanetriol alginate caffeine, as anticellulite agents, on fatty tissue: histological evaluation. J. Cosmet. Dermatol., 2008, 7, 23-29.
140. Kanikkannan N. Iontophoresis-based transdermal delivery systems. BioDrugs., 2002, 16, 339-347.
141. Mitragotri, S.; Kost, J. Low-frequency sonophoresis: a review. Adv. Drug Deliv. Rev., 2004, 56, 589-601.
142. Escobar-Chávez, J.J.; Bonilla-Martínez, D.; Villegas-González, M.A.; Rodríguez-Cruz, I. M.; Domínguez-Delgado, C.L. The use of sonophoresis in the administration of drugs throughout the skin. J. Pharm. Pharm. Sci., 2009, 12, 88-115.
143. Ogura, M.; Paliwal S.; Mitragotri, S. Low-frequency sonophoresis: current status and future prospects. Adv. Drug. Deliv. Rev., 2008, 60, 1218-1223.
144. Pires-de-Campos, M.S.; Leonardi, G.R.; Chorilli, M.; Spadari-Bratfisch, R.C.; Polacow, M. L; Grassi-Kassisse, D.M. The effect of topical caffeine on the morphology of swine hypodermis as measured by ultrasound. J. Cosmet. Dermatol. 2008, 7, 232-237.
145. Santoianni, P.; Nino, M.; Calabro, G. Intradermal drug delivery by low-frequency sonophoresis (25 kHz). Dermatol. Online J., 2004, 10, 24.
146. Liu, H.; Li, S.; Pan, W.; Wang, Y.; Han, F.; Yao, H. Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A. Int. J. Pharm., 2006, 326, 32-38.
147. Aggarwal, S. What's fueling the biotech engine-2007. Nat. Biotechnol., 2008, 26, 1227-1233.
148. Melnikova, I. Psoriasis market. Nat. Rev. Drug., Discov., 2009, 8, 767-768.
149. Rozenblit, M.; Lebwohl, M. New biologics for psoriasis and psoriatic arthritis. Dermatol. Therapy., 2009, 22, 56-60.